{"schema_version":"secwatch.filing_event.v1","accession":"0000896622-25-000026","form_type":"8-K","ticker":"ATR","cik":"0000896622","company_name":"APTARGROUP, INC.","filed_at":"2025-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.638587+00:00","generated_at":"2026-05-17T22:38:27.246411+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AptarGroup Q2 2025: adj. EPS $1.66 (+18% YoY), sales $966M (+6%), adj. EBITDA margin 22.6%","bullets":["Reported sales $966M (+6% YoY); core sales +3%; net income $112M (+24%); adj. EPS $1.66 vs $1.41.","Pharma core +3% (Injectables +9%, Active Material Science +11%); adj. EBITDA margin 35.4% (+130 bps).","Closures core +7% (food & bev); Beauty core +1% (personal care up, fragrance subdued).","Q3 adj. EPS guidance $1.53-$1.61; includes ~$0.06-$0.07 legal fees for pharma IP litigation.","Returned $100M to shareholders ($70M buybacks, $30M dividends); quarterly dividend $0.45 payable Aug 14."],"urls":{"canonical":"https://secwatch.observer/filing/0000896622-25-000026","json":"https://secwatch.observer/filing/0000896622-25-000026.json","markdown":"https://secwatch.observer/filing/0000896622-25-000026.md","text":"https://secwatch.observer/filing/0000896622-25-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/896622/000089662225000026/0000896622-25-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/896622/000089662225000026/atr-20250731.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T22:38:27.246411+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}